CELL BIOLOGY • APPLIED CELL BIOLOGY AND DISEASE

Metastasis Steps — Explain metastasis steps conceptually (EMT, invasion, intravasation, colonization) (intro)

How cancer cells escape a primary tumor, travel through the vasculature, and colonize distant organs.

Historical Context & Motivation

For most of medical history, cancer was understood as a localized disease—a malignant mass that could be surgically excised if caught early. The realization that tumors could spread to distant sites transformed oncology from a largely surgical discipline into a field requiring systemic approaches. Metastasis, the process by which cancer cells disseminate from a primary tumor to form secondary colonies in remote tissues, accounts for approximately 90 % of cancer-related mortality. Understanding the molecular steps that drive metastasis has therefore become one of the most consequential goals in biomedical research, shaping everything from chemotherapy regimens to the development of targeted immunotherapies.

1889
Seed and Soil Hypothesis
Stephen Paget analyzed over 900 autopsy records and proposed that metastasis is not random: cancer cells (the seeds) colonize only organs whose microenvironment (the soil) is compatible.
1928
Ewing's Mechanical Theory
James Ewing challenged Paget's idea, arguing that metastatic patterns could be explained purely by circulatory anatomy and hemodynamics, emphasizing vascular routes of dissemination.
1982
Discovery of E-cadherin's Role
Identification of E-cadherin as a key adhesion molecule. Subsequent work showed that loss of E-cadherin is a hallmark of the epithelial-mesenchymal transition (EMT), linking cell biology to metastatic progression.
2000s
EMT–MET Framework Formalized
Jean-Paul Thiery and others formalized the concept that carcinoma cells undergo reversible EMT and MET (mesenchymal-epithelial transition) to navigate the metastatic cascade, unifying decades of observations into a coherent molecular model.
2011
Hallmarks of Cancer Updated
Hanahan and Weinberg updated their landmark 'Hallmarks of Cancer' paper to include invasion and metastasis as a core hallmark, while recognizing enabling characteristics such as genome instability and tumor-promoting inflammation.

The central question driving modern metastasis research is deceptively simple: How does a stationary epithelial cell acquire the ability to migrate, survive in circulation, and re-establish proliferative growth in a foreign tissue? Answering this question requires an understanding of a sequential, multi-step cascade—each step presenting a distinct biological barrier that the cell must overcome.

Core Principles of the Metastatic Cascade

Metastasis is not a single event but a metastatic cascade—an ordered series of biological steps, each of which must be completed for a cancer cell to successfully seed a secondary tumor. These steps can be organized into four major phases: epithelial-mesenchymal transition (EMT), local invasion, intravasation and survival in circulation, and extravasation and colonization. A failure at any single step aborts metastasis entirely, which explains why the process is remarkably inefficient—fewer than 0.01 % of cells that enter the bloodstream successfully form a macrometastasis.

1

Epithelial-Mesenchymal Transition (EMT)

Carcinoma cells reprogram their gene expression, downregulating epithelial markers (E-cadherin) and upregulating mesenchymal markers (N-cadherin, vimentin). This grants motility, invasiveness, and resistance to apoptosis.
2

Local Invasion

EMT-activated cells degrade the basement membrane and invade the surrounding extracellular matrix (ECM) using matrix metalloproteinases (MMPs) and invadopodia, navigating through stromal tissue toward blood vessels.
3

Intravasation & Circulation

Cancer cells breach the endothelial lining of blood or lymphatic vessels. Once in circulation, they are called circulating tumor cells (CTCs) and must resist shear stress, anoikis, and immune surveillance.
4

Extravasation & Colonization

CTCs arrest at a distant capillary bed, cross the endothelium again (extravasation), and attempt to proliferate. Surviving cells may enter dormancy or, if the microenvironment is permissive, undergo MET and colonize—forming a secondary tumor.
KEY TAKEAWAY
Think of metastasis like a prison break across international borders. EMT is the prisoner learning to pick locks and disguise themselves (acquiring new abilities). Invasion is tunneling out of the cell block (breaching the basement membrane). Intravasation is jumping onto a moving freight train (entering the bloodstream), where the harsh ride kills most passengers. Colonization is reaching a new country and building a life from scratch—something only a tiny fraction of escapees manage, because the foreign environment is hostile. Each step requires a distinct skill set, and failure at any point ends the journey.

The Metastatic Cascade — Visual Overview

The metastatic cascade, from left to right: ① Cancer cells within the primary tumor undergo EMT, transitioning from rounded epithelial morphology (circles) to elongated mesenchymal forms (triangles). ② They invade through the extracellular matrix using MMPs. ③ Intravasation allows entry into a blood vessel, where they circulate as CTCs. ④ At a distant site, they extravasate and colonize the target organ.

The diagram above presents the metastatic cascade as a linear sequence, but it is important to appreciate that these steps are interconnected through feedback loops and microenvironmental signals. For instance, signals from distant organs can precondition a pre-metastatic niche even before the first cancer cell arrives, secreting exosomes and cytokines that prime the soil for future colonization. Similarly, the degree of EMT may be partial rather than complete—cells can exist in hybrid epithelial/mesenchymal states that offer both motility and the ability to form cell clusters, which paradoxically survive circulation better than single cells. These nuances underscore the importance of viewing metastasis as a dynamic, adaptable process rather than a fixed pipeline.

Molecular Mechanisms Underlying Each Step

Step 1 — Epithelial-Mesenchymal Transition (EMT)

In normal epithelia, cells are tightly connected by adherens junctions, tight junctions, and desmosomes, with E-cadherin serving as the central adhesion molecule. During EMT, transcription factors such as SNAIL, SLUG, TWIST, and ZEB1/2 are upregulated by signals from TGF-β, Wnt, Notch, and receptor tyrosine kinase pathways. These transcription factors directly repress the CDH1 gene (encoding E-cadherin) and activate genes for mesenchymal proteins including N-cadherin, vimentin, and fibronectin. The net result is a cell that detaches from its neighbors, reorganizes its actin cytoskeleton into stress fibers, becomes motile, and acquires resistance to apoptosis—a phenotype fundamentally suited for invasion.

Step 2 — Local Invasion

Once freed from epithelial constraints, the cancer cell must penetrate the basement membrane—a dense sheet of type IV collagen, laminin, and proteoglycans—and migrate through the stromal extracellular matrix (ECM). This is accomplished through secretion of matrix metalloproteinases (MMPs)—zinc-dependent endopeptidases that cleave collagen, elastin, and other ECM components. MMP-2 and MMP-9, which degrade type IV collagen, are particularly important. Cancer cells also extend actin-rich protrusions called invadopodia that concentrate protease activity at the leading edge, physically drilling through tissue barriers. Chemotactic gradients of EGF, CXCL12, and other factors guide directional migration toward blood vessels.

Step 3 — Intravasation & Survival in Circulation

To enter the bloodstream or lymphatic system, cancer cells must cross the endothelial barrier. Tumor-associated macrophages often assist this process, forming paracrine signaling loops with cancer cells near blood vessels—a phenomenon termed TMEM (tumor microenvironment of metastasis) doorways. Once in circulation, cells face extreme shear forces (blood flow can reach 1–10 dyn/cm²), anoikis (apoptosis triggered by loss of ECM attachment), and immune attack by natural killer (NK) cells and macrophages. Circulating tumor cells (CTCs) counteract these threats by coating themselves with platelets, which shield them from immune recognition and shear stress, and by traveling in clusters that have up to 50-fold greater metastatic potential than single cells.

Step 4 — Extravasation & Colonization

CTCs arrest at distant capillary beds, where the narrow vessel diameter physically traps them. Adhesion molecules such as selectins and integrins mediate attachment to the endothelium. The cells then transmigrate across the vessel wall into the parenchyma of the target organ—a process that mirrors leukocyte extravasation during inflammation. Once in the new tissue, the cancer cell faces the greatest bottleneck: colonization. The foreign microenvironment often lacks the growth factors, ECM composition, and stromal support the cell evolved in. Many cells enter a state of dormancy, remaining quiescent for months to decades. Those that eventually reactivate may undergo mesenchymal-epithelial transition (MET)—the reverse of EMT—recovering proliferative capacity and forming a clinically detectable macrometastasis.

Molecular players and attrition at each cascade step. The bottom bar illustrates the dramatic cell loss during metastasis: of the millions of cells that may invade locally, fewer than 0.01 % succeed in forming a distant colony. This inefficiency makes colonization the true rate-limiting step of the cascade.

The EMT Spectrum and Organ Tropism

Partial EMT and the Hybrid State

A major revision of the original EMT model is the recognition that tumor cells frequently exist in hybrid epithelial/mesenchymal (E/M) states rather than fully converting from one phenotype to the other. Cells in a hybrid state retain some epithelial features—such as partial cell–cell adhesion—while simultaneously expressing mesenchymal markers that confer motility. This allows them to migrate collectively as clusters rather than as isolated cells. CTC clusters have been shown to have a 23- to 50-fold higher metastatic potential than individual CTCs, likely because they resist anoikis, evade immune detection more effectively, and carry stromal cells that provide survival signals.

The Epithelial–Mesenchymal Phenotype Spectrum
Fully Epithelial
Hybrid E/M
Fully Mesenchymal
MET (re-epithelialization)
E-cadherin⁺, stationary
Cluster migration, max metastatic potential
Single-cell migration, invasive
Proliferative, colonization
EpithelialMesenchymal

Organ Tropism — Why Certain Cancers Metastasize to Specific Sites

Paget's seed-and-soil hypothesis has been validated at the molecular level. The concept of the pre-metastatic niche explains organ tropism: primary tumors secrete exosomes containing specific integrins that "address" them to particular organs. For example, exosomal integrin α6β4 targets the lungs, while integrin αvβ5 targets the liver. These exosomes reprogram resident stromal cells, recruit bone marrow-derived cells, and remodel the ECM, creating a hospitable microenvironment before cancer cells arrive.

Common metastatic tropism patterns and their molecular underpinnings.
Primary CancerCommon Metastatic SitesKey Molecular Mediators
Breast carcinomaBone, lung, liver, brainCXCR4/CXCL12 axis, RANKL, PTHrP
Colorectal carcinomaLiver (via portal vein), lungVEGF, MMPs, Wnt pathway
Prostate carcinomaBone (osteoblastic lesions)Endothelin-1, BMPs, αvβ3 integrin
MelanomaLung, liver, brain, skinBRAF/MAPK, exosomal integrins
Lung adenocarcinomaBrain, bone, adrenal, liverEGFR, CXCL12, COX-2

Worked Example — Tracing a Breast Cancer Cell Through the Metastatic Cascade

Consider a ductal carcinoma cell in the breast. Using the metastatic cascade framework, trace the molecular events that would enable this cell to form a bone metastasis.

Breast-to-Bone Metastasis Walkthrough
1
Step 1 — EMT InitiationThe ductal carcinoma cell is exposed to TGF-β secreted by cancer-associated fibroblasts (CAFs) in the tumor stroma. TGF-β activates SMAD signaling, which upregulates SNAIL and TWIST transcription factors. SNAIL binds the E-box motifs of the CDH1 promoter, silencing E-cadherin expression. The cell gains N-cadherin and vimentin expression, loses apical-basal polarity, and adopts a spindle-shaped morphology.
Cell transitions to a mesenchymal phenotype with increased motility and anoikis resistance.
2
Step 2 — Invasion Through Basement Membrane and ECMThe mesenchymal-like cell secretes MMP-2 and MMP-9, degrading the type IV collagen of the ductal basement membrane. Invadopodia, enriched with cortactin and MT1-MMP, extend into the stromal ECM. The cell follows a chemotactic gradient of EGF toward nearby blood vessels, using integrin-mediated adhesion (α5β1 integrin binding fibronectin) to pull itself through the matrix.
Cell successfully breaches the basement membrane and migrates through the stroma to a blood vessel.
3
Step 3 — Intravasation and Circulatory SurvivalAt a TMEM doorway—a triad of a cancer cell, a perivascular macrophage, and an endothelial cell—the macrophage secretes VEGF, transiently increasing vascular permeability. The cancer cell squeezes between endothelial cells and enters the bloodstream. As a CTC, it binds platelets via tissue factor and P-selectin, forming a protective cloak. This platelet shield blocks NK cell-mediated lysis and shields the cell from the shear forces of arterial flow.
CTC survives circulation as a platelet-coated entity, evading immune destruction and physical stress.
4
Step 4 — Extravasation at BoneThe CTC is attracted to the bone marrow by the CXCL12 chemokine gradient—bone marrow stromal cells constitutively secrete CXCL12, and the breast cancer cell expresses the CXCR4 receptor. The cell arrests in the sinusoidal capillaries of the bone marrow, adheres to the endothelium via E-selectin and VCAM-1/α4β1 integrin interactions, and transmigrates into the marrow parenchyma.
Cell extravasates into the bone marrow microenvironment, guided by CXCL12/CXCR4 signaling.
5
Step 5 — Colonization and Dormancy EscapeInitially, the disseminated tumor cell enters dormancy in the perivascular niche, held quiescent by BMP signaling and thrombospondin-1. After a latency period (potentially years), changes in the niche—such as inflammation or osteoclast-mediated bone remodeling releasing TGF-β from the bone matrix—reactivate the cell. The cell undergoes partial MET, re-expressing E-cadherin and forming proliferative microcolonies. It secretes PTHrP, stimulating osteoclastic bone resorption in a 'vicious cycle' that releases growth factors (IGF-1, TGF-β) from the bone matrix, fueling further tumor growth.
A clinically detectable osteolytic bone metastasis forms via the PTHrP–RANKL vicious cycle.

Therapeutic Strategies Targeting Metastatic Steps

Because metastasis is a multi-step process, each step presents a potential therapeutic intervention point. However, the clinical reality is that most anti-metastatic strategies remain in preclinical or early clinical development, in part because metastasis is often already underway by the time a primary tumor is diagnosed. The table below outlines the current landscape of strategies targeting each cascade step, along with their strengths and limitations.

Summary of therapeutic strategies targeting each step of the metastatic cascade.
Metastatic Step TargetedTherapeutic StrategyStrengthsLimitations
EMTTGF-β receptor inhibitors (e.g., galunisertib); HDAC inhibitors to restore E-cadherinPrevents acquisition of invasive phenotype early in cascadeTGF-β has tumor-suppressive roles in early cancer; systemic inhibition causes pleiotropic side effects
InvasionMMP inhibitors (e.g., marimastat, batimastat)Directly block ECM degradationPhase III trials failed due to musculoskeletal toxicity and lack of specificity; some MMPs are anti-tumorigenic
Intravasation / CirculationAnti-platelet agents (aspirin); anti-tissue factor antibodiesDisrupts platelet shielding; epidemiological data supports aspirin's anti-metastatic effectBleeding risk; timing of intervention (must be given before CTC dissemination)
ColonizationBisphosphonates / denosumab (bone); maintaining dormancy signalsBisphosphonates inhibit osteoclasts, disrupting the vicious cycle in bone metastasisOrgan-specific; cannot prevent all metastatic sites; dormancy escape mechanisms are poorly understood
CLINICAL REALITY
The failure of broad-spectrum MMP inhibitors in clinical trials during the late 1990s was a watershed moment for the field. It taught researchers that the metastatic cascade is not simply a matter of proteolysis—it involves intricate cell–cell signaling, immune evasion, metabolic reprogramming, and microenvironmental crosstalk. Modern approaches increasingly focus on immunotherapy (enabling the immune system to eliminate CTCs and micrometastases) and on maintaining cancer cell dormancy rather than trying to block a single molecular step. Think of it like airport security: instead of building a single, impenetrable gate, modern strategies layer multiple checkpoints—any one of which can catch an escaping cell.

Connections to Advanced Topics in Metastasis Biology

The introductory model of the metastatic cascade presented in this lesson provides a solid conceptual foundation, but advanced research has revealed additional layers of complexity. The table below highlights how several concepts introduced here connect to active areas of investigation that you will encounter in upper-division oncology and molecular biology courses.

How introductory metastasis concepts connect to advanced research topics.
Introductory ConceptAdvanced Extension
EMT as a binary switchEMT plasticity: cells occupy a continuum of hybrid E/M states regulated by coupled regulatory networks (miR-200/ZEB, miR-34/SNAIL double-negative feedback loops). Mathematical models (e.g., Cascades model by Jolly et al.) predict stable hybrid states.
Seed-and-soil hypothesisPre-metastatic niche formation: exosome-mediated organ priming, BMDC recruitment, LOX-mediated ECM remodeling at future metastatic sites before tumor cell arrival.
CTC survival in bloodLiquid biopsy: CTCs and circulating tumor DNA (ctDNA) as non-invasive biomarkers for real-time monitoring of metastatic progression and treatment response.
Dormancy at distant sitesDisseminated tumor cell (DTC) biology: perivascular niche regulation, autophagy as a survival mechanism, immune equilibrium maintaining dormancy, reactivation triggers.
Immune evasion by CTCsImmunoediting in metastasis: PD-L1 expression on CTCs, neutrophil extracellular traps (NETs) promoting extravasation, cancer-associated immunosuppression via myeloid-derived suppressor cells (MDSCs).

Perhaps the most exciting frontier is the integration of single-cell transcriptomics and spatial transcriptomics with metastasis research. These technologies allow researchers to map the gene expression profiles of individual cells within a tumor, identifying the rare subpopulations that are primed for metastasis. Combined with lineage-tracing experiments in mouse models, these approaches are revealing that metastatic competence may be established much earlier in tumor evolution than previously appreciated—possibly at the stage of a pre-malignant lesion.

Practice Problems

PROBLEM 1CONCEPTUAL
Explain why E-cadherin is often described as a 'tumor suppressor' in the context of metastasis. What happens to E-cadherin expression during EMT, and how does this change promote metastatic behavior?
PROBLEM 2BASIC CALCULATION
A primary tumor sheds approximately 1 × 10⁶ cells into the circulation daily. If the overall efficiency of metastasis (from intravasation to successful colonization) is 0.005 %, how many cells per day would be expected to form micrometastases? If only 1 in 100 of those micrometastases escapes dormancy and becomes a clinically detectable macrometastasis over 5 years, how many macrometastases might develop?
PROBLEM 3INTERMEDIATE
A researcher observes that treating breast cancer cells with a specific TGF-β receptor inhibitor in vitro prevents EMT (cells retain E-cadherin expression) but does not reduce cell proliferation. In a mouse xenograft model, the treated tumors grow at the same rate as controls but produce significantly fewer lung metastases. Propose a mechanistic explanation for these results. Would you predict that this drug would be effective if administered only after metastatic disease is already established?
PROBLEM 4APPLIED
Liquid biopsy of a patient's blood reveals a high count of CTC clusters expressing both E-cadherin and vimentin. The patient's primary tumor is a colorectal carcinoma. Based on your understanding of the metastatic cascade: (a) What phenotypic state are these CTCs in? (b) Why might CTC clusters have higher metastatic potential than single CTCs? (c) Which organ(s) would you predict to be at highest risk for metastasis, and what molecular axis drives this tropism?
PROBLEM 5CRITICAL THINKING
Some researchers have proposed that the traditional linear model of metastasis (primary tumor → EMT → invasion → intravasation → colonization) may be oversimplified. Evidence suggests that metastatic seeding can occur even from pre-malignant lesions and that early-disseminated cancer cells may evolve in parallel with the primary tumor at distant sites. How would this 'parallel progression model' change our understanding of (a) the role of EMT, (b) the timing of therapeutic intervention, and (c) the relationship between primary tumor size and metastatic risk?

Lesson Summary

The metastatic cascade is a sequential, multi-step process through which cancer cells spread from a primary tumor to distant organs. It begins with the epithelial-mesenchymal transition (EMT), in which carcinoma cells downregulate E-cadherin and upregulate mesenchymal markers under the control of transcription factors like SNAIL, TWIST, and ZEB, acquiring motility and invasiveness. Local invasion follows, driven by matrix metalloproteinases (MMPs) and invadopodia that degrade the basement membrane and ECM. Cells then undergo intravasation to enter the vasculature, becoming circulating tumor cells (CTCs) that survive shear stress and immune attack through platelet cloaking and cluster formation.

At distant sites, CTCs arrest in capillary beds, extravasate, and attempt colonization—the rate-limiting step, with fewer than 0.01 % of CTCs succeeding. Organ tropism is governed by Paget's seed-and-soil hypothesis and the molecular concept of the pre-metastatic niche. Cells may enter dormancy for years before reactivating via mesenchymal-epithelial transition (MET) to form macrometastases. Understanding each step of the cascade provides targets for therapeutic intervention—from TGF-β inhibitors blocking EMT, to immunotherapies eliminating CTCs, to bisphosphonates disrupting bone colonization—and underscores that metastasis is a remarkably inefficient but ultimately lethal process responsible for the vast majority of cancer deaths.

Varsity Tutors • Cell Biology • Metastasis Steps — EMT, Invasion, Intravasation, Colonization